||
/ / ' / / / , / / / / / / / , , / ó㳺 / / / ³ / /
ϳ . . ... , 2006 -

˲

.. ̳ / / ó. - 2001. - . 3. - 5. - . 156-160.

.., .., .. / / . - 2005. - . 13. - 17. - . 2-3.

.., .. . - 2005. - . 17-33.

.., ., Ѳ. . - .: , 1998. - 244 .

.., .. . - ., 1998.

.., ͳ Ѳ., .. - 1 / / . - 2001. - 4. - . 8 - 13.

볺 .., .. , / / . -2002. - 5. - . 65-68.

.., .. . - .: , 1985. - 229 .

.., .. ̳ ij-35 / / . - 2001. - 6. - . 22-25.

: ' . - 2004. - . 31.

.. , / / . ... . . . - . 1995. - 145 .

.. . - .: ., 2000. - . 199.

' . ' . - Baltimore JHPIPGO, 1999. -. 85-98.

.., .., .. ճ / / . - 2000. - 2. - . 7-8.



.. -. - .: , 1999.

.. - 㳺: . ... . . . - ., 1993.

.. --- - : . . ... . . . - ., 1986.-25 .

.. 㳿. - ., 2000.

/ . .. - ., 1995.

() / ϳ . - .. - .: , 2000. - 190 .

. . / / . - 2002. - . 8. - 6. - . 48.

.. / / . - 2001. - 1. - . 26.

.. : . . ... . . . -., 2001. ~ . 25.

. , () / / -. - 2001. - 5. - . 16.

.. - : . ... . . . - ., 2000.

/ . .. - .: , 1998. - 216 .

ij .., .., .. / / . 㳿. - 1995. - 2. - . 8-10.

ij .., .., .. . - ., 2003. - 96 .

.. . - .: , 1983.-. 408.

.. - : . ... . . . - ., 1988. - 155 .



.. . - . - .: , 1993. - . 198-263.

.. - : . . ... . . . -., 1991.-24 .

dz .., .., .., .. - -- / / . - 1988. - 11.-. 50-53.

/ / '. - 2000. - 1.-. 18-19.

AM. - / / ³. . - 2004. - 6. - . 20-25.

- / . .., .. -., 2003. - . 21-24.

.., .. Գ / / . . . - 1998. - 4. - . 54-58.

.. - acne / / - '. - 2001. - 3. - . 35-37.

, , 2004. - 157 .

.. . / / ' . - 2000. - 2. - . 31-39.

.. / / ' . - 1998. - 11 2.-. 11.

.., .. - / / ' . - 2005. - 1. - . 14-17.

.., .., .. / / . - 1996. - 6. -. 6-7.

.., .., .. / / ó. - 2000. - 2. - . 36-41.



.., .. : . - .: , 2002. - 717.

.., Ѻ .., .., .. '. - ., 1997. - 297 .

.., .. 㳿. - ., 2000. - . 252-268.

.., .., .. - 㳿. - ., 2000. - . 613-637.

˺ . - / / ó. - 1988. - . 31. - 6. -. 633-638.

.., .., .. / / . - 2001. - 5. - . 39-43.

.. . - ., 1993. - 195 .

⳿ .. / / ' . - 2004. - 1. - . 56-57.

.. ' , , 㳿 / / ó. - 2001. - . 3. - 4. - . 37-39.

.. / / ' . - 1998. - 1. - . 11-17.

.. ' 1- : . . ... . . . - ., 2006.

(, , ) / . .., .. - ., 1996. - 64 .

- . / / . - 2004. - . 46-49.

Ъ. : . ... . . . - ., 1991. - 154 .

/ . .. - .: , 2005. - 624 .

.. / / . - 1991. - 12. - . 63.

.. - / / ó. - 2005. - . 7. - 4. - . 224-226.



.. / / ³ -. - 1999. - 3. - . 1-4.

.., .. 㳿 : - / / ó -2005. -. 7. - 1.

., .. / / ó. - 2004. - . 6. - 3. - . 111-113.

.., .. / / -. - 2001. - 2. - . 60-64.

.., .. / .: ó . - ., 2004. - . 283-320.

., .. ' / / . . - 1999. - !. - . 12-14.

.. - : . ... . . . - 2003. - 26 .

' / / , VI . - ., 2004.

㳿 / / . .., Գ .. - .: -., - 2001. - . 165.

Ѳ. : . . ... . . . - 1993. - 25 .

.. / / . - 2002. - 6. - . 26-29.

/ . .. . . -1994. -. 251-295.

㳿 / ϳ . ³- .. - .: ̲, 1998. - 765 .

.., .. ̳ / / . - 2000. - 2. - . 6.

.., .. / .: 㳿. - ., 2005. -. 185-223.

Ѻ .. ̳ (') / / ³ -. - 2001. - 2. - . 62-65.



Ѻ .., .., .. -- 㳿. - --: , 1998. - . 232-239.

ѳ .., . . - ., 1998.-. 97-113.

Ѻ .., .., .. ó . - .: , 2004. - 520 .

Ѻ .., .., .. 㳿. - ., 1995.-426 .

Ѻ .., .., , ., . / / ³ -. - 1996. - 1. -. 88-91.

.., .. . -.: . ., 2000. - 292 .

/ / / . . .. - 1998. - . 80-98.

.. / / . - 1989. - 4. -. 6-11.

.., .. , / / . . - 1998. - 3. - . 41-45.

.., .. 㳺 / / . - 2002. - 5. - . 24-28.

, . - ̳ : . . ... . . . - 2001. - 26 .

.. 35 / / . ... . . . - ., 1990. - 162 .

人 .. : . . ... . . . - , 1995. - 25 .

糺 .., .., . / / . - 1988. - 1. - . 51-53.



.., .., .. / / . - 1995. - 7. - . 43.

.., .. / / ó. - 2005. - 1.

.. ó ﳿ . - .: , 2004. -. 17-20.

. / / . -1988. - 8. -. 50-54.

.. ճ / / -. - 2001. - 3 (5). - . 50-51.

㳿 / ϳ . .., - .. - ., 1999. - . 350-356.

Abrams L., Skee D., Natarajan J. etal. Pharmacokinetics of a contraceptive patch (Evra / Ortho Evra) containing norelgestromin and ethinylestradiol at four application sites / / Br. J. Clin. Pharmacol., 2002, 53, 141-146.

Aden U., Jung-Hoffmann C, Kuhl H. A randomized cross-over study on various hormonal parameters of two triphasic oral contraceptives. Contraception, 1998, 58, 75-81.

Ahren ., Victor A., ??Lithell H. et al. Ovarion function, bleeding control and serum lipoproteins in women using contraceptive vaginal rings releasing five different progestins / / Contraception, 1983, 28,315-327.

American Diabetes Association: Clinical Practice Recommendations 2001. Preconception Care of Women with Diabetes / / Diabetes Care, 2001, 24 Suppl.
l, 23-28.

Amory J.K., Bremner W.J. Newer agents for hormonal contraception in the male / / Trends in Endocrinology and Metabolism, 2000, 11 (2), 61-66.

Andersson K., Odlind V., Rybo G, Levonorgestrel-releasing and copper-releasing (Nova T) IUDs during five years of use: a ran-domisod comparative trial / / Contraception, 1994, 49, 1, 56-72.

Andersson K., Rybo G Levonorgestrel-releasing intrauterine device in the treatment of menorrhagia / / Brit. J. Obstet. Gynecol., 1990. 97, 690-694.

Andrist L.C. et al. Women's and providers attitudes toward menstrual suppression with extended use of oral contraceptives / / Contraception, 2004, 70, 359-363.



Andrist LC, Hoyt J., Weinstein D., McGibbon The need to bleed: women's attitudes and beliefs about menstrual suppression / / J. Am. Acad. Nurse Pract., 2004, 16 (1), 31-7.

Antoniou G., Kalogirou D., Karakitsos P. et al. Transdermal estrogen with a levonorgestrel-releasing intrauterine device for climacteric complaints versus estradiol-releasing vaginal ring with a vaginal progesterone suppository: clinical and endometrial responses / / Maturitas, 1997, 26, 2, 103-111.

Archer D., BigriggA., Smallwood G. et al. Assessment of compliance with a weekly contraceptive patch (Ortho Evra / Evra) among North American Women / / Fertil Steril., 2002, 77 (2), 27-31.

ARHP / NPWH. Obstacles to using extended contraceptive regimens / / Clin. Proa, 2003, (April), 1 1-2.

Audet M.-C, Moreau M., Koltun W. et al. For the ORTHO EVRA / EVRA 004 Study Group. Evaluation of contraceptive efficacy and cycle control of a transdermal contraceptive patch vs an oral contraceptive / / JAMA, 2001, 285, 2347-2354.

Back D.J., Orme M. L.E. Pharmacokinetic drag interactions with oral contraceptives / / Clin. Pharmacokinetic, 1990, 18, 472-84.

BaksuA., Gunes G., Aki G. et al. Change in contraceptive choices and the effect of education on use of contraception at the family planning clinic of Sisli Etfal Training and Research Hospital, Istanbul, Turkey / / Eur. J. Contracept. Reprod. Health Care, 2005 Jun, 10 (2), 98-104.

Ballagh A., Mishell D., Lacarra M. et al. A contraceptive vaginal ring releasing norethindrone acetate and etinyl estradiol / / Contraception, 1994, 50, 517-533.

Barbosa I., Bakos O., Olsson S. et al. Ovarian function during use of levonorgestrel-releasing IUD / / Contraception, 1990, 42, 51-66.

Barbosa J., Olsson S.E., Odlend V. et al. Ovarian function after seven years use of a levonorgestrel IUD / / Adv. Contraception, 1995, 11,2,85-95.

Barentsen R., Van de Weijer P. Progestogens: Pharmacological characteristics and clinically relevant differences / / European Menopause J., 1996, 3, 4, 266-271.

Barrington J., Bowen-Simpkins P., The levonorgestrel intrauterine system in the management of menorrhagia / / Brit. J. Obstet. Gynecol., 1997, 104, 5, 614-616.

Barrington J.W., Leary A.O., Bowen-Sinpkins P. Management of refractory pre-menstrual syndrome using subcutaneous oestradi-ol implants and levonorgestrel intrauterine systems / / J. Obstet. Gynecol., 1997, 17,4,416-417.



Bebb R., Anawalt ., Christensen R. et al. A promising male contraceptive approach: combined administration of testosterone and levonorgestrel / / J. Clin. Endocrinol. Metab., 1996, 81, 757-762.

Benenson A.B., Wiemann CM. Use of levonorgestrel implants versus oral contraceptives in adolescence. A case-control study / / Amer. J. Obstet. Gynecol., 1995, 172, 41, 1128-1137.

Bigelow J., Dunson D., Stanford J. et al. Mucus observations in the fertile window: a better predictor of conception than timing of intercourse / / Hum. Reprod., 2004 Apr, 19 (4), 889-92.

Birkhauser M., Braendle W., Breckwoldt M. et al. 24th Workshop of the Zurcher Gesprachskreis May 2000: recommendations on oral contraception, Frauenarzt, 2000, 41, 1053-8.

Blanchard K. Life without menstruation / / The Obstetrician Gynecologist, 2003, 5, 34-37.

Bloemenkammp K., Rosendaal F.R., Helmerhost F. Enhancement by factor V Leiden mutation of risk of deep-vein thrombosis associated with oral contraceptives containing a third-generation progestagen / / Lancet., 1995, 348, 1593.

Bloemenkamp KWM, Rosendaal FR, Helmerhorst FM et al. Higher risk of venous thrombosis during early use of oral contraceptives in women with inherited clotting defects / / Arch. Intern. Med., 2000, 160, 49-52.

Brady B.M., Anderson R.A. Advances in male contraception / / Expert Opinion on Investigational Drugs, 2002, 11 (3), 333-344.

Brascen M.B. Oral contraception and congenital malformation in offspring: a rewiew and meta-analis of the prospective studies / / Obstet. Gynecol., 1990, 53, 21.

Cachrimanidou A.A. et al. Hemostasis profile and lipid metabolism with long-interval use of a desogestrel-containing oral contraceptive / / Contraception, 1994, 50, 153-165.

Caliskan E., Ozturk N., Dilbaz B. et al. Analysis of risk factors associated with uterine perforation by intrauterine devices / / Eur. J. Contracept Reprod. Health Care, 2003 Sep, 8, 3, 150-5.

Chomczyk I., Sipowicz M., Sipowicz I. Dydrogesteron in the regulation of cycle disturbances in adolescence / / Gin. Pol., 1999, 70, 343-347.

Chuong C.J., Brenner P.F. Management of abnormal uterine bleeding / / Am. J. Obstet. Gynecol., 1996, 175, 787-92, 59.

Colburn P., Buonassisi V. Estrogen-binding sites in endothelial cell cultures / / Science, 1978, 201, 817-9.

Coleman M., Cowan L., Farquhar The levonorgestrel-releasing intrauterine device: a wider role than contraception / / Aust. NZ Obstet. Gynecol., 1997, 37, 2, 195-201.



Coutinho E.M., de Souza J.C., CsapoA.I. Reversible sterility induced by medroxyprogesterone injections / / Fertil. Steril., 1966, 17, 261-266.

Coutinho E.M., Segal S.J. Is menstruation obsolete? How suppressing menstruation can help women who suffer from anemia, endometriosis or PMS. New York, Oxford University Press,

1999, 11.

Critchley H., WangH., Kelly R. etal. Progestin receptor isoforms and prostaglandin dehydrogenase in the endometrium of women using a levonorgestrel-releasing intrauterine system / / Hum. Reprod., 1998, 13,5, 1210.

Crosignani P., Vercellini P., Mosconi P. etal. Levonorgestrel-releasing intrauterine device versus hysteroscopic endometrial resection in the treatment of dysfunctional uterine bleeding / / Obstet. Gynecol., 1997, 90, 257-263.

Cwiak C, Gellasch ., Zieman M. Peripartum contraceptive attitudes and practices / / Contraception, 2004 Nov., 70 (5), 383-6.

Davis K.R., Weller S.C. The effectiveness of condoms in reducing heterosexual transmission of / / Family Planning Perspectives, 1999, 31,6, 272-279.

Diamond P. Contraception in diabetic women / / Clin. Obstet. Gynecol., 1991, 34, 3, 565-571.

Edelman A. Menstrual nirvana: amenorrhea through the use of continuous oral contraceptives / / Curr Womens Health Rep., 2002, 2, 434-438.

Emergency contraception Pills: Medical and service delivery guidelines. Second Edition, 2004. International Consortium for Emergency contraception, Washington DC, USA.

Eraser I.S., Jansen R.P.S. Why do inadvertent pregnancies occur in oral contraceptive users? Effectiveness of oral contraceptive regimens and interfering factors / / Contraception, 1983, 27, 531-51.

Farrow A., Hull M.G.R., Northstone K. et al. Prolonged use of oral contraception before a planned pregnancy is associated with a decreased risk of delayed conception / / Hum. Reprod., 2002, 10, 2754-61.

Fedele L. et al. Use of the levonorgestrel-releasing intrauterine device in the treatment of rectovaginal endometriosis / / Fert. Steril., 2001, 75, 485-488.

Ferguson Ft., Vree M., Willlshaar J. Multicenter study of the efficacy, cycle control and tolerability of a phasic desogestrel-containing oral contaceptive / / Eur. J. Contracept. Reprod. Health Care,

2000, 5, 35-45.

Filshie G.M. Laparoscopic female sterilization / / Baillieres Clin. Obstet. Gynecol., 1989, 3, 609.



Fonseca-Montinho J, Lacerda M., Prazeres H.P. et al. Expression of estrogen and progesterone receptors in CTN III and cervical sguamous cell microinvasive carcinoma. An immunohistochem-ical study / / Int. J. Cancer 18th UICC Internacional Cancer Congress, 2002, Suppl. 13, 763.

Foster R.H., Wilde M.I. Dienogest / / Drugs, 1998, 56, 825-833.

Fotherby K. Interactions with oral contraceptives / / Am. J. Obstet Gynecol., 1990, 163,2153-9.

Friedman A.J., Thomas P.P. Does low-dose combination oral contraceptive use affect uterine size of menstrual flow in premenopausal women with leiomyomata / / Obstet. Gynecol., 1995, 85, 631-5.

Fuhrmann U., Krattenmacher R., Slater E. et al. The novel progestin drospirenone and its natural counterpart progesterone: biochemical profile and antiandrogenic potential / / Contraception, 1996, 54, 243-251.

Gallo M. et al. Nonlatex vs. latex male condoms for contraception: a systematic review of randomized controlled trials / / Contraception, 2003 (November), 68, 5, 319-326.

Graham J., Clarke C. Physiological action of progesterone in target tissues / / Endocr. Rev., 1997 Aug, 18, 4, 502-519.

Gu Z., Zhu P., Luo H. et al. Morphometric study on the endometrial activity of women before and after one year with LNG-IUD in situ / / Contraception, 1995, 52, 57-61.

Handelsman D.J. Contraception in the male. In: DeGroot LJ, editor. Endocrinology. 3rd edition. Philadelphia: WB Saunders, 1995: 2449-2458.

Harvengt C. Effect of oral contraceptive use on the incidence of impaired glucose tolerance and diabetes mellitus / / Diabete Metabolisme, 1992, 18, 71-77.

Hatcher R.A., Trussed J., Stewart F. et al. Contraceptive Technology. Eighteenth Revised Edition. NY, Ardent Media, 2004.

Ho P., Kwan M. A prospective randomized comparison of lev-onorgestrel wits the Yuspe regimen in post-coital contraception / / Hum. Reprod., 1993, 8, 389-92.

Hubacher D. et al. Use of copper intrauterine devises and the risk tubal infertility among nulligravid women / / New England Journal of Medicine, 2001, 345, 561-567.

Hurk P., O'Brien S. Non-contraceptive use of the levonorgestrel-releasing intrauterine system / / Obstet. Gynecol., 1999, 1, 1, 13-19.

Ingegno M., Money S., Theimo W. etal. Progesterone receptors in the human heart and great vessels / / Lab. Invest., 1988, 59, 353-6.

Irvine G., Campbell-Brown M., Lumsden M.et al. Randomised comparative trial of the levonorgestrel intrauterine system and



norethisterone for treatment of idiopathic menorrhagia / / Brit. J. Obstet. Gynecol., 1998, 105, 6, 592-598.

Jarvela I., TekayA., Jouppila P. The effect of a levonorgestrel-releas-ing intrauterine system on uterine artery bloodflow, hormone concentrations and ovarian cyst formation in fertile women / / Hum. Reprod., 1998, 13, 12, 3379-3383.

Jespersen J., Petersen K.R. et al. Effect of new oral contraceptives on the inhibition of coagulation and fibrinolisis in relation with dosage and type Steroid / / Am. J. Obst. Gynecol., 1990, 136, 396-403.

Jick H., Jick S., Gurewich V. et al. Risk of idiopathic cardiovascular death and nonfatal venous thromboembolism in women using oral contraceptives with differing progestagen components / / Lancet, 1995,346, 1589-1593.

Johansson E. Future aspects of the levonorgestrel-releasing intrauterine system / / Gynecol. Forum, 1998, 3, 3, 311-32.

Jung-Hoffmann , Kuhl H. interaction with the pharmacokinetics of ethinylestradiol and progestins contained in oral contraceptives Contraception, 1989, 40, 299-312.

Jung-Hoffmann C, Heidt F., Kuhl H. Effect of two oral contraceptives containing 30 mkg ethinylestradiol and 75 mkg gestodene or 150 (mkg desogestrel upon various hormonal parameters / / Contraception, 1998, 38, 593-603.

Kelsey J. Hormonal contraception and lactation / / J. Hum. Lact., 1996 Dec, 12, 4, 315-8.

Killick S.R., Bancroft K, Oelbaum S. etal. Extending the duration of the pill-free interval during combined oral contraception / / Adv. Contracept, 1990, 6, 33-40.

Klein B.E.K., Moss S.E., Klein R. Oral contraceptives in women with diabetes / / Diab. Care, 1990, 13, 895-8.

Konje J., Otolorin E., Odukoya O. Return of ovulation after removal Norplant subdermal implants / / Brit. J. Family Planning, 1995, 18, 2, 44-46.

Kuhl H., Gahn G., Romberg G. el al. A randomized cross-over comparison of two low-dose oral contraceptives upon hormonal and metabolic parameters. 1: effects on sexual hormone levels / / Contraception, 1985, 31, 583-93.

Lahteenmaki P., Bardin C, Eloma K. et al. Selection and performance of the levonorgestrel-releasing intrauterine system / / Obstet. Gynecol. Scand., 1997, 164, 69-74.

Loudon N.B., Potta D.M. et al. Acceptability of an oral contraceptive that reduces the frequency of menstruation, fhe tri-cucle regimen / / BMJ, 1997, 2, 487-490.



Marions L., Hultenby K. et at. Emergency contraception with mifepristone and levonorgestrel: mechanism of action / / Obstet. Gynecol., 2002, 100,65-71.

Marshall L.M., Spiegelman D., Goldman M.B. et al. A prospective study of reproductive factors and oral contraceptive use in relation on the risk of uterine leiomyomata / / Fertil. Steril., 1998; 70: 432-9.

Mauck C, Lai J., Schwartz J. et al. Diaphragms in clinical trials: Is clinician fitting necessary? / / Contraception, 2004, 24, 4, 263-266.

Meckstroth K, Barney P. Implantable contraception / / Obstet. Gynecol. Clin. North. Am., 2000 Dec, 27, 4, 781-815.

Meriggiola M., Bremner W., Paulsen C. et al. Cyproterone acetate and testosterone enanthate as a potentially highly effective male contraceptive / / J. Clin. Endocrinol. Metab., 1996, 81, 3018-3023.

Mikolajczyk R., Stanford J., Rauchfuss M. Factors influencing the choice to use modern natural family planning / / Contraception, 2003 Apr, 67, 4, 253-8.

Miller L., Hughes J.P. Continuous combination oral contraceptive pills to eliminate withdrawal bleeding: a randomized trial / / Obstet. Gynecol., 2003, 101, 653-670.

Million Women Study Collaborators Breast cancer and hormone-replacement therapy in the Million Women Study / / Lancet, 2003, 362, 419, 27, 52.


Milman N.. Clausen J., Byg K.E. Iron status in 268 Danish women aged 18-30 years influence of menstruation, contraceptive method, and iron supplementation / / Ann. Hematol., 1998, 77, 13-9.

Moore C, Feichtinger W., Klinger G. et al. Clinical findings with the dienogest-containing oral contraceptive Valette / / Drugs of Today, 1999, 35 (Suppl. C), 53-68.

Moore C, Kohler G, MullerA. The treatment of endometriosis with dienogest / / Drug of Today, 1999, 35 (Suppl. C), 69-79.

Moore C, Luderschmidt C, Moltz. L. et al. Antiandrogenic properties of the dienogest-containing oral contraceptive Valette / / Drugs of Today, 1999, 35 (Suppl. C), 69-79.

Mulders ., Dieben T. Use of the novel combined contraceptive vaginal ring NuvaRing for ovulation inhibition / / Fertil. Steril., 2001, 75, 865-870.

National womens health network statement on using an extended cycle of oral contraceptives for menstrual suppressions. [Seasonale]. Retrieved January 14, 2004.

Newton J. Classification and comparison of oral contraceptives containing new generation progestogens / / Hum. Reprod. Update, 1995, 1,231-263.



Nilsson C, Lahteenmaki P., Luukkainen T. Ovarian function in amenorrheic and menstruating users of a levonorgestrel-releasing intrauterine device / / Fertil. Steril., 1984, 41, 1, 52-55.

Oelkers W. Effects of estrogens and progestogens on the renin-aldosterone system and blood pressure / / Steroids, 1996, 61, 166-71.

Oelkers W., FoidartJ., Dombrovicz N. etal. Effects of a new oral contraceptive containing an antimineralocorticoid progestogen, drospirenon, on the renin - aldosterone systems, body weight, blood pressure, glucose tolerance and lipid metabolism / / J. Clin. Endocrinol. Metab., 1995, 80, 1816-21.

Oettel M., Carol W., Elger W. et al. A 19-nonprogestin without a 17a-ethinyl group. 11: Dienogest from a pharmacodynamic point of view / / Drugs of Today, 1995, 31 (Suppl), 517-536.

Oettel M., Graser ., Hoffmann H. et al. The preclinical and clinical profile of dienogest. A short overview / / Drugs of Today, 1999, 35 (Suppl. C), 3-12.

Oinonen K.A., Mazmanian D. To what extent do oral contraceptives influence mood and affect? / / J. Affect. Disord., 2002, 70, 229-40, 65.

Olsson S.E., Wide L., Odlind V. Aspects of thyroid function during use Norplant implants / / Contraception, 1986, 34, 583-587.

Ortayli N, Bulut A., Ozugurlu M., Cokar M. Why withdrawal? Why not withdrawal? Men's perspectives / / Reprod. Health Matters, 2005 May, 13,25, 164-73.

Pakarinen P., Toivonen J., Luukkainen T. Randomized comprasion of a levonorgestrel-and copper-releasing intrauterine system immediately after abortion, with 5 years follow up / / Contraception, 2003, 68,31-34.

Penttilla L, Makkonen M., Castren O. Thyroid function during treatment with a new oral contraceptive combination containing des-ogestrel / / Europ. J. Obstetr. Gynecol. Reprod. Biol., 1983, 16, 269-274.

Perheentupa A., Critchley H., Illingworth P. et al. Effect of progestin-only pill on pituitary-ovarian axis activity during lactation / / Contraception, 2003 Jun, 67, 6, 467-71.

Peterson A., Perez-Escamilla R., Labbok M. et al. Multicenter study of the lactational amenorrhea method (LAM) 111: effectiveness, duration, and satisfaction with reduced client-provider contact / / Contraception, 2000 Nov, 62, 5, 221-30.

Raymond E.G., Chen P.L., Luoto J. Spermicide Trial Group. Contraceptive effectiveness and safety of five nonoxynol-9 spermicides: a randomized trial / / Obstetrics & Gynecology, 2004, 103,3,430-439.

Resenbaum P., Schmidt W., Helmerhorst F. etal. Inhibition of ovulation by a novel progestogen (drospirenone) alone or in combina-



tion with ethinylestradiol / / Eur. J. Contracept. Reprod. Health Care, 2000, 5, 16-24.

Rogovskaya S.L, Rivera R., Grimes D.A. et al. Effect of a lev-onorgestrel intrauterine system on women with type 1 diabetes: a randomized trial / / Report. Research Group. The American college of Obstetricians and Ginecologists, 2005, 105, 4, 811-815.

Rosenberg M., Long S. Oral contraceptives and cycle control: A critical review of the literature / / Advances in Contraception, 1992, Suppl 1, 35-45.

Rosendaal F. R. Thrombosis in the young epidemiology and risk factors A focus on venous thrombosis. Thrombos Haemost., 1997, 78, 1-6.

Roumen F., Apter D., Mulders T. et al. Efficacy, tolerability and! acceptability of a novel contraceptive vaginal ring releasing etonogestrel and ethinylestradiol / / Hum. Reprod., 2001, 16, 469-475.

Roumen F., Boon M., van Velzen D. etal. The cervico-vaginalepithelium during 20 cycles use of a combined contraceptive vaginal ring / / Hum. Reprod., 1996, 11, 2443-2448.

Ruchhoft E., Elkind-Hirsch K.E., Malinak R. Pituitary function is altered during the same cycle in women with polycystic oyary syndrome treated with continuous of cyclic oral contraceptives of a gonadotropin-releasing hormone agonist / / Fertil. Steril., 1996, 66, 54-60.

Rutanen E. Endometrial response to intrauterine release of lev-onorgestrel / / Gynecology Forum, 1998, 3, 3, 11-13.

Rutter W., Knight C, Vizzard J., Mira M., Abraham S. Womens attitude to withdrawal bleeding and theirt knowledge and beliefs about oral contraceptive pill / / Med. J. Austr., 1988, 149, 417-9.

Rybo G. Tretment of menorrhagia using intrauterine administration oflevonorgestrel / / Gynecology Forum, 1998, 3, 3, 20-22.

SchindlerA., Campagnoli et al. Aspects of progestin activity on the brest / / Maturitas, 1998, 29, 61-65.

Senanayake P., Potts M. An Atlas of Contraception. New York, London, 1995,77-82.

Sibai ., Odlind V., Meador M. et al. A comparative and pooled analysis of the safety and tolerability of the contraceptive patch (Ortho Evra / Evra) / / Fertil. Steril., 2002, 77 (Suppl 2), 19-26.

Sivin L, Stern J. Health during prolonged use levonorgestrel 20 micrograms / d and the copper TCu 380A intrauterine contraceptive devises: a multicenter study / / Fertility Sterility, 1994, 61, 70-77.

SmallwoodG, Meador M., Lenihan J. etal. For the ORTHO EVRA / EVRA 002 Study Group. Efficacy and safety of a transdermal contraceptive system / / Obstet. Gynecol., 2001, 98, 799-805.



Sotaniemi E. Contraceptive failure in the United State / / J. Med., 2003,9, 117-128.

Spona J., Elstein M., Feichtinger W. et al. Shorter pill-free itnterval in combined oral contraceptives decreases follicular development / / Contraception, 1996, 54, 71-7.

Stanczyk F. Structure-function relationships, metabolism, phama-cokinetics and potency of progestins / / Drugs of Today, 1996, 32 (Suppl. H), 1-14.

Stanford J.L., Brinton L.A., Berman M.L. et al. Oral contraceptives and endometrial cancer, do other risk factors modify the association? / / Int. J. Cancer, 1993, 54, 243-8.

StanwoodN., Grimes D., SchulzK. Insertion of an intrauterine devise after induced spontaneous abortion: a review of the evidence / / International Journal of Obstetrics & Gynecology, 2001, 108, 1168-1173.

Steiner M. et al. Contraceptive effectiveness of a polyurethane condom and a latex condom: a randomized controlled trial / / Obstetrics & Gynecology, 2003 (March), 101 (3), 539-547.

Stewart A. et. al. The effectiveness of the levonorgestrel-releasing intrauterine system in menorrhagia: a systematic review / / BJOG: an International Journal of Obstetrics & Gynecology,

2001, 108,74-86.

Sturridge F., Guillebaund /., Gynecological aspects of the levonorgestrel-releasing intrauterine system / / Brit. J. Obstet. Gynecol., 1997, 104, 3, 285-289.

Suhonen S., Alonen H., Lahteenmaki P. Sustained-release estradiol implants and levonorgestrel-releasing intrauterine device in hormone replacement therapy / / Am. J. Obstet. Gynecol., 1995, 172, 562-567.

Suhonen S., Holmstrom ., Allonen H. et al. Intrauterine and subder-mal progestin administration in postmenopausal hormone replacement therapy / / Fertil. Steril., 1995, 63, 336-342.

Sulak P., Scow R.D., Precce et al. Hormone withdrawal symptoms in oral contraceptive users / / Obstet. Gynecol., 2000, 95, 261-6, 64.

Sulak P.J., Kuehl T.J., Ortiz M. et al. Acceptance of altering the stan-dart 21-day/7-day oral contraceprive regimen to delay menses and reduce hormone withdrawal symptoms / / Am. J. Obstet.,

2002, 186, 1142.

Sulak P.J., Cressman B.E., Waldrop E. et al. Extending the duration of active oral contraceptive pills to manage hormone withdrawal symptoms / / Obstet. Gynecol., 1997, 89, 179-83, 38.

Sullivan H., Furniss H., Spona J. et al. Effect of 21-day and 24-day oral contraceptive regimens containing gestodene (60 mkg) and



ethinylestradiol (15mkg) on ??ovarian activity / / Fertil. Steril., 1999,72, 115-20.

Svemdottir H., Backstrom T. Prevalence of menstrual cycle symptom cyclicity and premenstrual dysphoric disorder in a random sample of women using and not using oral contraceptives / / Acta Obstet. Gynecol. Scand., 2000, 79, 405-13.

TimmerC, Apter D., Voortman G. Pharmacokinetics of 3 keto-deso-gestrel and ethinylestradiol released from different types of contraceptive vaginal rings / / Contraception, 1990, 42, 629-642.

TimmerC, Mulders T. Pharmacokinetics of etonogestrel and ethinylestradiol released from a combined contraceptive vaginal ring / / Clin. Pharmacokinet., 2000, 39, 233-242.

Toivonen J., Luukkainen ., Allonen H. Protective effect of intrauterine release of levonorgestrel on pelvic infection: three years 'comparative experience of levonorgestrel and copper-releasing intrauterine devices / / Obstet. Gynecol., 1991, 77, 2, 261-264.

Truitt S., FraserA., Grimes D. et al. Hormonal contraception during lactation. Systematic review of randomized controlled trials / / Contraception, 2003 Oct, 68, 4, 233-238.

Vercellini P. et al. A levonorgestrel-releasing intrauterine system for the treatment of dysmenorrhea associated with endometriosis: a pilot study / / Fertil. Steril., 1999, 72, 505-508.

Vercellini P., De Giorgi O., Mosconi P. et al. Cyproterone acetate versus a continuous monophasic oral contraceptive in the treatment of recurrent! pelvic pain after conservative surgery for symptomatic endometriosis / / Fertil. Steril., 2002, 77, 52-61.

WHO. Effectiveness of male latex condoms in protecting against pregnancy and sexually transmitted infections. World Health Organization Fact Sheet No. 243. Geneva: WHO (June 2000).

WHO. Medical eligibility criteria for contraceptive use. Third edition. Geneva, 2004.

WHO. Selected practice recommendations for contraceptive use. Second edition. Geneva, 2005.

Wiegratz L., Hummel H.H., Zimmermann T. et al. Attitudes of German women and gynecologists towards long-cycle treatment with oral contraceptives / / Contraception, 2004, 69, 37-42.

Wilkinson D. et al. Nonoxynol-9 for preventing vaginal acquisition of sexually transmitted infections by women from men (Cochrane Review). In: Cochrane Library, Issue 4. Oxford: Update Software (2002).

Winkler U.H. Haemostatic activite indused by gestoden and norges-timat containing low-dose oral contraceptives. Hightlights of XIV FIGO wolrd congress. Montreal, 1994, 10-16.

World Health Organisation Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception. Effect of different



progestogens in low oestrogen oral contraceptives on venous throm-boembolic disease / / Lancet, 1995, 346, 1582-1588.

World Health Organization Task Force on long-acting systemic agents for fertility regulation: a multicenter phase HI comparative clinical trial of depot-medroxyprogesterone acetate given three monthly at doses of 100 mg or 150 mg. Contraceptive efficacy and side effects / / Contraception, 1986, 34, 223-235.

World Health Organization Task Force on Methods for the Regulation of Male Fertility. Contraceptive efficacy of testosterone-induced azoospermia and oligozoospermia in normal men / / Fertil. Steril., 1996, 65, 821-829.

World Health Organization. Multinational comparative clinical evaluation of two long-acting injectable contraceptive steroids. Norethindrone enanthate and medroxyprogesterone acetate. Final, report / / Contraception, 1983, 28, 1-20.

Wii F.C.W., Farley T.M.M., Peregoudov A. et al. Effects of testosterone enanthate in normal men: experience from a multicentre contraceptive efficacy study / / Fertil. Steril., 1996, 65, 626-636.

Yuspe A., Thurlow H., Ramzy I. et al. Postcoital contraception - a pilot study / / J. Reprod. Med., 1974, 13, 53-58.

Zieman M., Guillebaud J., Weisberg E. et al. Contraceptive efficacy and cycle control with the Ortho Evra / Evra transdermal system: the analysis of pooled data / / Fertil. Steril., 2002, 77 (2), 13-18.

Zimmermann H., Duvauchelle ., Gualano V. etal. Pharmacokinetics of dienogest as a single drag or in combination with estradiol valerate or ethinylestradiol / / Drugs of Today, 1999, 35 (Suppl. C), 27-39.

Zimmermann ., Dietrich ., Wisser K. et al. Efficacy and tolerabili-ty of the dienogest-containing oral contraceptive Valette. Results of a postmarketing surveillance study / / Drugs of Today, 1999, 35 (Suppl. C), 79-87.



в ֲ

. . ..

³ : ..

: ..

: ..ϳ

: ..

' : ..

˳ 04317 20.04.01 . ϳ 14.03.06. 84x108/32. . . 12,5 . . 3000 . 613

-.

107140, , . , .1, 1

: 105062, , / 63

E-mail: office@med-press.ru

www.med-press.ru

³

105005, , . . , 46
= =
, "˲"
  1. ˲Ͳ ղί
    , . : I.
  2. ó .
    , , , , , . (),

  3. () 1768 . , . , 0,7%
  4. Բֲ òDz
    () - 㳿, . Riedel J. Widimsky (1987): 1. ϳ . 2. ³ . 3. ³
  5. ϲ
    "ﳺ" -' , - . , -, , ,

  6. . , . , .

  7. . , , , , '
  8. . .
    , ' , , , (). 1958 . , "Ciba". ³ '

  9. . , , . ', 㳿,

  10. . . Laenec (1819), , . ³ (1978), , ,
© medbib.in.ua -